Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 18/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | CDK7 | P50613 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL949179 | 0.94 | CHEK1 (0.52) | CHEK1GSK3BDYRK1ACDK7 | |
| SCHEMBL948987 | 0.94 | CHEK1 (0.52) | CHEK1GSK3BDYRK1ACDK7 | |
| SCHEMBL948800 | 0.92 | CHEK1 (0.52) | CHEK1GSK3BDYRK1ACDK7 | |
| SCHEMBL952011 | 0.92 | CHEK1 (0.49) | CHEK1GSK3BDYRK1ACDK7 | |
| SCHEMBL949307 | 0.92 | CHEK1 (0.51) | CHEK1GSK3BDYRK1AKLKB1CDK7 | |
| SCHEMBL12946276 | 0.90 | CHEK1 (0.49) | CHEK1GSK3BDYRK1AKLKB1CDK7 | |
| SCHEMBL952082 | 0.89 | CHEK1 (0.50) | CHEK1GSK3BDYRK1A | |
| SCHEMBL12946168 | 0.89 | CHEK1 (0.45) | CHEK1 | |
| SCHEMBL951004 | 0.88 | CHEK1 (0.47) | CHEK1 | |
| SCHEMBL948391 | 0.88 | CHEK1 (0.46) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS R&D LTD (GB) | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK2, CHEK1, BUB1B | CHEK1 2/4885GSK3B 511/4885DYRK1A 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.